A breakthrough clinical trial in gene editing by RheumaGen is revolutionizing the treatment of autoimmune disorders. RG0401 targets specific HLA alleles to encode molecules found in individuals resistant to rheumatoid arthritis. By extracting a patient’s hematopoietic stem cells (HSCs) and introducing engineered HLA alleles ex vivo, the therapy aims to create cells with modified HLA […]